Scalper1 News
Specialty drugmaker AMAG Pharmaceuticals (AMAG) agreed to acquire stem-cell bank Cord Blood Registry for $700 million Monday, sending AMAG’s stock on a volatile ride. CBR owns about 600,000 units of umbilical-cord blood and tissue stem cells, which its partners use in medical research. Last year, the company drew $126 million in revenue, about the same as AMAG itself, which currently gets its income from three drugs used to treat anemia and oral Scalper1 News
Scalper1 News